Immatics
IMTX | NASDAQ
$6.17
-$0.22 (-3.44%)
At close: Nov 16, 2026, 4:00 PM ET
$6.29
+$0.12 (+1.94%)
After-hours:
Nov 16, 2026, 5:29 PM ET
Immatics Company Profile
Company profile explainedCompany Profile
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Key Executives
| Name | Position |
|---|---|
| Harpreet Singh | Chief Executive Officer, MD, Member of Management Board & Executive Director |
| Amie Krause | Chief People Officer |
| Venkat Ramanan | Chief Financial Officer |
| Carsten Reinhardt | Chief Development Officer |
| Ephraim Hofsäß | Vice President of SEC Reporting & Accounting |
| Hans-Georg Rammensee | Co-Founder & Member of the Scientific Advisory Board |
| James Pepin | General Counsel & Corporate Secretary |
| Lauren Schroeder | Vice President of Marketing |
| Rainer Kramer | Chief Business Officer & Site Head Munich |
| Steffen Walter | Chief Operations Officer |
| Toni Weinschenk | Co-Founder & Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 6-K | Filing |
| Oct 23, 2026 | 6-K | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 27, 2026 | SC 13D/A | [Amend] Filing |
| Aug 26, 2026 | 6-K | Filing |
| Aug 25, 2026 | 424B2 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 6-K | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 29, 2026 | 3 | Filing |
Immatics
| Country | Germany |
| IPO Date | Dec 12, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 704 |
| CEO | Harpreet Singh |
Contact Details
Paul-Ehrlich-Strasse 15 Tübingen,
BW 72076 Germany
Stock Details
| Ticker Symbol | IMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001809196 |
| CUSIP Number | N44445109 |
| ISIN Number | NL0015285941 |
| SIC Code | 2836 |
Recent News
- 6 days ago / zacks.comImmatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
- 6 days ago / globenewswire.comImmatics Announces Third Quarter 2026 Financial Results and Business Update
- 8 days ago / zacks.comImmatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- 24 days ago / globenewswire.comImmatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
- 3 months ago / seekingalpha.comImmatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
- 3 months ago / globenewswire.comImmatics Announces $150 Million Underwritten Offering
- 3 months ago / globenewswire.comImmatics Announces Second Quarter 2026 Financial Results and Business Update
- 5 months ago / seekingalpha.comImmatics: PRAME Is Becoming More Than A Single-Asset Story
- 6 months ago / globenewswire.comImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
- 6 months ago / zacks.comImmatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Add to Watchlist
Select watchlists to add or remove IMTX